High uric acid level linked to coronary stent restenosis

(HealthDay)—A high level of serum uric acid prior to implantation of bare-metal coronary stents predicts stent restenosis, according to research published in the Jan. 15 issue of The American Journal of Cardiology.

Osman Turak, M.D., of the Turkiye Yuksek Ihtisas Training and Research Hospital in Ankara, Turkey, and colleagues analyzed data from 708 consecutive patients (mean age, 60.3 ± 9.3 years; 71 percent men) with stable or unstable angina pectoris who received bare-metal coronary stents. The authors sought to assess the association between serum uric acid (SUA) level and in-stent restenosis (ISR).

The researchers found that, among patients grouped by tertiles according to preprocedural SUA level, stent restenosis occurred in 23 percent in the lowest tertile, 34 percent in the middle tertile, and 46 percent in the highest tertile. Independent predictors of ISR identified by multiple logistic regression analysis included diabetes mellitus, smoking, high-density lipoprotein cholesterol level, stent length, C-reactive protein level, and preprocedural SUA level. Further analysis showed that SUA level greater than 5.5 mg/dL had 75 percent sensitivity and 71 percent specificity in predicting ISR.

"In conclusion, higher preprocedural SUA is a powerful and independent predictor of bare-metal stent restenosis in with stable and unstable angina pectoris," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Procedural results from the RIBS V trial presented

Oct 30, 2013

A clinical trial comparing the use of drug-eluting stents (DES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from bare metal stents found that both techniques yielded positive long term outcomes. ...

Drug-Eluting stents reduce risk of thrombosis

Mar 23, 2012

(HealthDay) -- Cobalt-chromium everolimus eluting stents (CoCr-EES) are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting ...

Results of the SORT-OUT VI trial presented

Oct 30, 2013

A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible ...

Recommended for you

A global view on the prevention of cardiovascular disease

15 hours ago

The United Nations and the World Health Organization pledged in 2011 to reduce premature mortality from non-communicable diseases - most notably cardiovascular diseases - by 25% by the year 2025. It's an ambitious target, ...

Stroke healthcare inequalities remain in the UK

22 hours ago

The quality of healthcare provided after a stroke remains uneven in the UK, according to a new study led by King's College London. Despite improvements in equal access to healthcare since 2001, patients from ...

FDA approves expanded indication for CRT devices

Apr 15, 2014

(HealthDay)—The U.S. Food and Drug Administration has approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers (CRT-P) and eight cardiac resynchronization ...

User comments